Chang‐Gong Liu

Active 1997–2022

Also published as
Chang Gong Liu · Chang–Gong Liu · Chang-Gong Liu · Chang-gong Liu
93
Papers
52,765
Citations
85
h-index
92
i10-index

Citations

Citations per year for Chang‐Gong Liu1975: 3 citations1986: 1 citations1992: 8 citations1996: 1 citations1998: 8 citations1999: 15 citations2000: 6 citations2001: 10 citations2002: 12 citations2003: 3 citations2004: 24 citations2005: 82 citations2006: 361 citations2007: 735 citations2008: 1,413 citations2009: 1,840 citations2010: 1,917 citations2011: 1,728 citations2012: 1,523 citations2013: 1,345 citations2014: 1,007 citations2015: 777 citations2016: 584 citations2017: 627 citations2018: 414 citations2019: 1,525 citations2020: 1,362 citations2021: 1,090 citations2022: 676 citations2023: 475 citations2024: 602 citations2025: 233 citations2026: 4 citations1976–1985: no citations, so these years are not shown1987–1991: no citations, so these years are not shown1993–1995: no citations, so these years are not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,898 citing papers, 26.9% of this breakdownChina: 3,782 citing papers, 20.8% of this breakdownItaly: 985 citing papers, 5.4% of this breakdownGermany: 758 citing papers, 4.2% of this breakdownUnited Kingdom: 702 citing papers, 3.9% of this breakdownJapan: 540 citing papers, 3% of this breakdownCanada: 381 citing papers, 2.1% of this breakdownFrance: 380 citing papers, 2.1% of this breakdownIran: 373 citing papers, 2.1% of this breakdownIndia: 369 citing papers, 2% of this breakdownAustralia: 353 citing papers, 1.9% of this breakdownSpain: 345 citing papers, 1.9% of this breakdown
0%26.9%Other 23.7%

Fields

  • Biochemistry, Genetics and Molecular Biology75.1%
  • Medicine19.9%
  • Immunology and Microbiology2.4%
  • Neuroscience0.6%
  • Agricultural and Biological Sciences0.5%
  • Engineering0.3%
  • Other1.2%

Topics

  • MicroRNA in disease regulation20.5%
  • Cancer-related molecular mechanisms research11.5%
  • Circular RNAs in diseases10.6%
  • RNA modifications and cancer4.7%
  • RNA Interference and Gene Delivery2.7%
  • RNA Research and Splicing2.6%
  • Other47.4%

Coauthors

All papers

Open in search
  1. A microRNA expression signature of human solid tumors defines cancer gene targets

    Authors: , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 5,696

  2. miR-15 and miR-16 induce apoptosis by targeting BCL2

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 3,521

  3. MicroRNA Gene Expression Deregulation in Human Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Research 2005 cited by 4,059

  4. tsRNA signatures in cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2017 cited by 290

  5. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis

    Authors: , , , , , , , , , , , , , - Cancer Cell 2006 cited by 3,048

  6. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 277

  7. Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 262

  8. Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock

    Authors: , , , , , , , , , , - The Journal of Immunology 2007 cited by 1,295

  9. MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma

    Authors: , , , , , , , , , , , , , - JAMA 2008 cited by 1,586

  10. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Research 2016 cited by 271

  11. MicroRNA Signatures in Human Ovarian Cancer

    Authors: , , , , , , , , , , , , - Cancer Research 2007 cited by 1,416

  12. A MicroRNA Signature of Hypoxia

    Authors: , , , , , , , , , , , - Molecular and Cellular Biology 2006 cited by 1,062

  13. MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis

    Authors: , , , , , , , , , - JAMA 2007 cited by 1,138

  14. MiR-15a and miR-16-1 cluster functions in human leukemia

    Authors: , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 806

  15. A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 2,412

  16. MicroRNA expression profiling using microarrays

    Authors: , , , - Nature Protocols 2008 cited by 293

  17. p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2

    Authors: , , , , , , , , , , , , , - The Journal of Experimental Medicine 2011 cited by 509

  18. Transcription Factor Foxo1 Is a Negative Regulator of Natural Killer Cell Maturation and Function

    Authors: , , , , , , , , , , , , , , , , , , , - Immunity 2015 cited by 184

  19. Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , - Cancer Research 2007 cited by 812

  20. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells

    Authors: , , , , , , , - Autophagy 2009 cited by 441

  21. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carlo Toniatti, Jason B. Fleming, Michael Goggins, Laura D. Wood, Alessandro Sgambato, Abbas Agaimy, Anirban Maitra, Charles W.M. Roberts, Huamin Wang, Andrea Viale, Ronald A. DePinho, Giulio Draetta, Lynda Chin - Nature 2017 cited by 131

  22. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2018 cited by 88

  23. MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior

    Authors: , , , , , , , , , , - Journal of Clinical Oncology 2006 cited by 778

  24. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2013 cited by 217